Entrada Therapeutics, Inc. (TRDA)

Entrada Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 7, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	385	612	503	424	534	-
Market Cap Growth	-36.38%	21.70%	18.72%	-20.71%	-	-
Enterprise Value	113	224	219	236	610	-
Last Close Price	10.08	17.29	15.09	13.52	17.12	-
PE Ratio	-	9.33	-	-	-	-
PS Ratio	6.75	2.90	3.90	-	-	-
PB Ratio	1.06	1.43	2.08	1.99	1.79	-
P/TBV Ratio	1.14	1.43	2.08	1.99	1.79	-
P/FCF Ratio	-	-	3.75	-	-	-
P/OCF Ratio	-	-	3.60	-	-	-
EV/Sales Ratio	1.83	1.06	1.69	-	-	-
EV/EBITDA Ratio	-	4.41	-	-	-	-
EV/EBIT Ratio	-	4.77	-	-	-	-
EV/FCF Ratio	-	-	1.63	-	-	-
Debt / Equity Ratio	0.15	0.14	0.28	0.12	-	-
Debt / EBITDA Ratio	-	0.92	4.68	-	-	-
Debt / FCF Ratio	-	-	0.51	-	-	-
Asset Turnover	0.13	0.42	0.36	-	-	-
Quick Ratio	13.74	10.78	2.26	8.62	43.32	11.62
Current Ratio	14.08	11.15	2.33	9.55	44.46	11.89
Return on Equity (ROE)	-27.11%	19.56%	-2.94%	-37.01%	-30.19%	-93.94%
Return on Assets (ROA)	-15.71%	5.90%	-0.55%	-21.79%	-18.29%	-53.97%
Return on Capital (ROIC)	-17.33%	7.36%	-0.72%	-22.63%	-18.86%	-59.03%
Return on Capital Employed (ROCE)	-31.30%	9.70%	-1.00%	-42.30%	-17.10%	-66.40%
Earnings Yield	-26.71%	10.72%	-1.33%	-22.33%	-9.57%	-
FCF Yield	-33.51%	-7.30%	26.68%	-22.82%	-10.38%	-
Buyback Yield / Dilution	-15.95%	-18.01%	-5.62%	-399.27%	-467.09%	-18.45%

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q